Up-regulation of POM121 is linked to prostate cancer aggressiveness and serves as a prognostic biomarker

Finn Becker, Anne Offermann, Marie C. Roesch, Vincent Joerg, Doris Roth, Verena Lubczyk, Rainer Kuefer, Verena Sailer, Jutta Kirfel, Axel S. Merseburger, Sven Perner*

*Corresponding author for this work


Purpose: Nucleoporins as components of the nuclear pore complex (NCP) are known for regulating nuclear-cytoplasmatic transport. Recently, the nucleoporin POM121 was found to have an important impact on intranuclear translocation of prostate cancer (PCa)-specific tumor drivers including the androgen receptor (AR). The aim of our study was to assess the potential of POM121 as a prognostic biomarker. Methods: Therefore, we performed immunohistochemistry (IHC) for POM121 on a large clinically, well characterized PCa tissue cohort comprising benign prostatic samples, radical prostatectomy (RPE) samples, lymph node metastases, local recurrent tumors and distant metastases of 289 patients. Using a semi automated tissue image analysis software we evaluated POM121 protein expression level based on IHC. Results: We could show that POM121 expression increases during tumor progression. Expression levels were significantly higher in primary tumors compared to benign samples (P = 0.001), and substantially higher in advanced tumors (P < 0.001) and in distant metastases (P = 0.006) compared to primary tumors. Furthermore, POM121 expression predicts biochemical recurrence free survival (BFS) after surgery independent of the WHO group and other clinicopathological markers. 5-years BFS with primary tumors lacking POM121 and expressing POM121 was 88.8% and 68.9%, respectively. Conclusion: Our study reveals the potential of POM121 as a potential biomarker for PCa, predicting BFS independent of other common clinicopathological parameters. Furthermore, POM121 might be a new targetable structure for patients suffering from advanced PCa.

Original languageEnglish
JournalUrologic Oncology: Seminars and Original Investigations
Issue number8
Pages (from-to)380.e11-380.e18
Publication statusPublished - 08.2022

Research Areas and Centers

  • Research Area: Luebeck Integrated Oncology Network (LION)
  • Centers: University Cancer Center Schleswig-Holstein (UCCSH)


Dive into the research topics of 'Up-regulation of POM121 is linked to prostate cancer aggressiveness and serves as a prognostic biomarker'. Together they form a unique fingerprint.

Cite this